INSP - Inspire Medical Systems Inc Stock Price, Fair Value and News

243.51USD+21.88 (+9.87%)Market Closed

Market Summary

USD243.51+21.88

Market Closed

9.87%

INSP Alerts

3 major insider sales recently.

INSP Stock Price

View Fullscreen

INSP RSI Chart

INSP Valuation

Market Cap

7.2B

Price/Earnings (Trailing)

-340.58

Price/Sales (Trailing)

11.53

EV/EBITDA

-411.41

Price/Free Cashflow

7.0K

INSP Price/Sales (Trailing)

INSP Profitability

Operating Margin

97.61%

EBT Margin

-3.19%

Return on Equity

-3.69%

Return on Assets

-3.13%

Free Cashflow Yield

0.01%

INSP Fundamentals

INSP Revenue

Revenue (TTM)

624.8M

Rev. Growth (Yr)

39.6%

Rev. Growth (Qtr)

25.57%

INSP Earnings

Earnings (TTM)

-21.2M

Earnings Growth (Yr)

368.67%

Earnings Growth (Qtr)

272.87%

Breaking Down INSP Revenue

Last 7 days

1.4%

Last 30 days

22.2%

Last 90 days

26.0%

Trailing 12 Months

-7.2%

How does INSP drawdown profile look like?

INSP Financial Health

Current Ratio

7.6

INSP Investor Care

Shares Dilution (1Y)

1.85%

Diluted EPS (TTM)

-0.72

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	466.4M	526.1M	570.2M	624.8M
2022	262.4M	300.9M	348.4M	407.9M
2021	134.4M	175.2M	201.0M	233.4M
2020	87.1M	81.3M	96.3M	115.4M
2019	56.8M	63.9M	71.7M	82.0M
2018	33.3M	38.2M	44.0M	50.6M
2017	19.5M	22.5M	25.5M	28.6M
2016	0	0	0	16.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Inspire Medical Systems Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 12, 2024	ellis gary lee	acquired	16,221	231	70.00	-
Apr 12, 2024	nelson marilyn c	acquired	24,796	231	107	-
Apr 12, 2024	tansey casey m	acquired	14,367	231	62.00	-
Apr 12, 2024	broader shelley g.	acquired	16,221	231	70.00	-
Apr 12, 2024	melenikiotou georgia	acquired	12,977	231	56.00	-
Apr 01, 2024	griffin jerry c	sold	-6,847	213	-32.00	-
Apr 01, 2024	herbert timothy p.	sold	-8,203,580	205	-40,000	ceo and president
Apr 01, 2024	griffin jerry c	acquired	4,736	16.00	296	-
Apr 01, 2024	nelson marilyn c	acquired	52,368	16.00	3,273	-
Mar 27, 2024	nelson marilyn c	acquired	294,633	90.8521	3,243	-

Which funds bought or sold INSP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	MCF Advisors LLC	unchanged	-	421	7,948	-%
Apr 16, 2024	Berger Financial Group, Inc	unchanged	-	18,210	344,309	0.03%
Apr 16, 2024	Sawyer & Company, Inc	unchanged	-	155	5,155	-%
Apr 15, 2024	Legato Capital Management LLC	added	56.59	144,206	364,928	0.04%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	sold off	-100	-81,575	-	-%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	added	8.14	37,570	302,639	-%
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	new	-	1,289	1,289	-%
Apr 12, 2024	Traynor Capital Management, Inc.	unchanged	-	12,496	236,269	0.02%
Apr 11, 2024	CONGRESS ASSET MANAGEMENT CO /MA	reduced	-7.09	-66,528	3,430,840	0.02%
Apr 11, 2024	Rheos Capital Works Inc.	added	25.83	4,218,000	17,054,000	0.82%

Are Funds Buying or Selling INSP?

Are funds buying INSP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INSP

No. of Funds

INSP Alerts

3 major insider sales recently.

Unveiling Inspire Medical Systems Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.93%	2,931,469	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 29, 2024	blackrock inc.	6.1%	1,800,118	SC 13G/A
Nov 13, 2023	fmr llc	-	0	SC 13G
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	10.31%	2,978,391	SC 13G/A
Jan 31, 2023	blackrock inc.	7.4%	2,135,708	SC 13G/A
Nov 10, 2022	vanguard group inc	10.04%	2,899,902	SC 13G/A
Feb 03, 2022	blackrock inc.	6.7%	1,846,227	SC 13G/A
Jan 10, 2022	fmr llc	-	0	SC 13G/A

Recent SEC filings of Inspire Medical Systems Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	144	Notice of Insider Sale Intent
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4/A	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to Inspire Medical Systems Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	183.7B	40.1B	-5.83%	1.66%	32.1	4.58	-8.12%	-17.45%
BDX	67.1B	19.5B	-2.32%	-8.43%	53.41	3.44	4.02%	-22.04%
ALGN	22.6B	3.9B	-4.99%	-13.70%	50.69	5.84	3.42%	23.09%
BAX	20.1B	14.8B	-4.86%	-7.71%	7.56	1.35	2.12%	209.17%
MID-CAP
ATR	9.1B	3.5B	-0.64%	16.68%	32.11	2.62	4.97%	18.89%
HSIC	9.0B	12.3B	-5.34%	-15.09%	21.69	0.73	-2.44%	-22.68%
BIO	8.5B	2.7B	-12.68%	-39.24%	-13.34	3.18	-4.68%	82.43%
XRAY	6.3B	4.0B	-7.94%	-25.15%	-46.81	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-1.55%	17.10%	-564.66	9.35	33.86%	89.83%
PDCO	2.3B	6.6B	-3.92%	-2.28%	11.91	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-5.32%	-19.06%	-1.85	0.39	7.73%	-1066.14%
ANIK	382.1M	166.7M	1.82%	-7.51%	-4.62	2.29	6.67%	-456.34%
ANGO	253.5M	324.0M	17.44%	-27.90%	-1.32	0.78	-3.19%	-337.41%
APYX	45.7M	52.3M	-25.42%	-56.00%	-2.44	0.87	17.61%	19.28%
AEMD	3.7M	3.7M	-14.97%	255.00%	-0.3	0.99	5.77%	8.23%

Inspire Medical Systems Inc News

Latest updates

Inspire Medical Systems Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	25.6%	192,508,000	153,302,000	151,092,000	127,897,000	137,900,000	109,188,000	91,386,000	69,382,000	78,398,000	61,685,000	52,959,000	40,352,000	46,009,000	35,842,000	12,183,000	21,347,000	26,906,000	20,862,000	18,032,000	16,250,000	16,559,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,193,000
Gross Profit	27.6%	164,454,000	128,920,000	126,840,000	108,009,000	115,748,000	89,402,000	77,213,000	59,378,000	67,242,000	53,061,000	45,441,000	34,371,000	38,848,000	30,631,000	10,229,000	18,050,000	22,667,000	17,406,000	14,938,000	13,396,000	13,366,000
Operating Expenses	9.0%	155,157,000	142,391,000	143,439,000	127,507,000	116,083,000	106,596,000	91,220,000	75,434,000	69,063,000	62,857,000	57,985,000	50,060,000	45,910,000	40,523,000	33,043,000	34,490,000	31,960,000	26,057,000	23,114,000	22,173,000	18,263,000
S&GA Expenses	9.6%	124,105,000	113,247,000	112,618,000	101,988,000	94,835,000	85,603,000	76,686,000	63,564,000	58,769,000	53,243,000	48,697,000	41,906,000	38,625,000	33,216,000	26,981,000	29,052,000	28,193,000	22,434,000	20,268,000	19,570,000	16,111,000
R&D Expenses	6.5%	31,052,000	29,144,000	30,821,000	25,519,000	21,248,000	20,993,000	14,534,000	11,870,000	10,294,000	9,614,000	9,288,000	8,154,000	7,285,000	7,307,000	6,062,000	5,438,000	3,767,000	3,623,000	2,846,000	2,603,000	2,152,000
EBITDA Margin	46.8%	-0.03	-0.05	-0.07	-0.08	-0.10	-0.13	-0.13	-0.15	-0.17	-0.22	-0.25	-0.40	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	656,000	494,000	527,000	538,000	537,000	530,000	523,000	533,000	533,000	526,000	525,000	530,000	529,000	523,000	537,000	689,000
Income Taxes	68.3%	505,000	300,000	214,000	200,000	146,000	246,000	100,000	100,000	31,500	3,000	26,000	-	28,000	87,000	-	-	40,000	-	-	-	-
Earnings Before Taxes	285.9%	15,240,000	-8,200,000	-11,738,000	-15,208,000	3,275,000	-16,601,000	-14,348,000	-16,594,000	-2,371,000	-10,344,000	-13,062,000	-16,193,000	-7,456,000	-10,298,000	-23,089,000	-16,245,000	-9,040,000	-8,247,000	-7,650,000	-8,266,000	-4,778,000
EBT Margin	43.0%	-0.03	-0.06	-0.08	-0.09	-0.11	-0.14	-0.15	-0.16	-0.18	-0.23	-0.27	-0.42	-	-	-	-	-	-	-	-	-
Net Income	272.9%	14,763,000	-8,540,000	-11,952,000	-15,424,000	3,150,000	-16,847,000	-14,490,000	-16,694,000	-2,391,000	-10,347,000	-13,088,000	-16,216,000	-7,484,000	-10,385,000	-23,089,000	-16,245,000	-9,080,000	-8,247,000	-7,650,000	-8,266,000	-4,778,000
Net Income Margin	41.1%	-0.03	-0.06	-0.08	-0.09	-0.11	-0.14	-0.15	-0.16	-0.18	-0.23	-0.27	-0.43	-	-	-	-	-	-	-	-	-
Free Cashflow	375.6%	9,234,000	-3,350,000	237,000	-5,097,000	16,319,000	7,490,000	-7,373,000	-13,963,000	201,000	-1,489,000	-11,777,000	-11,722,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	5.8%	677	639	618	572	565	528	292	290	295	279	272	273	281	272	271	166	181	183	186	190	200
Current Assets	4.2%	594	570	560	534	530	496	263	262	269	255	249	261	270	267	267	155	171	170	177	189	199
Cash Equivalents	-43.8%	186	330	467	442	442	418	187	203	214	210	177	182	191	179	211	76.00	23.00	48.00	51.00	102	97.00
Inventory	29.8%	34.00	26.00	21.00	16.00	12.00	15.00	22.00	22.00	17.00	16.00	13.00	11.00	8.00	9.00	10.00	7.00	6.00	5.00	4.00	3.00	3.00
Net PPE	24.0%	40.00	32.00	25.00	21.00	17.00	14.00	11.00	9.00	8.00	8.00	7.00	7.00	5.00	4.00	3.00	3.00	3.00	3.00	2.00	1.00	1.00
Liabilities	9.4%	104	95.00	89.00	67.00	69.00	57.00	65.00	65.00	66.00	59.00	52.00	50.00	51.00	43.00	38.00	38.00	41.00	37.00	33.00	32.00	36.00
Current Liabilities	11.6%	78.00	70.00	67.00	60.00	61.00	49.00	47.00	43.00	41.00	34.00	24.00	19.00	21.00	18.00	13.00	14.00	17.00	13.00	9.00	8.00	11.00
Shareholder's Equity	5.2%	573	544	529	505	496	470	227	225	229	220	220	223	230	229	234	127	140	146	152	157	164
Retained Earnings	4.1%	-345	-360	-351	-339	-324	-327	-310	-296	-279	-277	-266	-253	-237	-229	-219	-196	-180	-171	-162	-155	-146
Additional Paid-In Capital	1.4%	917	904	881	844	820	798	538	521	508	497	487	477	467	459	453	323	320	317	315	313	311
Accumulated Depreciation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00
Shares Outstanding	0.5%	30.00	29.00	29.00	29.00	29.00	28.00	28.00	28.00	27.00	27.00	27.00	27.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	9,352	-	-	-	4,966	-	-	-	5,161	-	-	-	2,229	-	-	-	1,071	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	374.6%	17,267	3,638	5,092	-1,344	19,269	11,002	-5,954	-12,748	734	-338	-10,114	-10,401	-4,110	-8,909	-25,251	-14,775	-6,076	-2,944	-12,884	-10,942	-2,589
Share Based Compensation	15.2%	22,849	19,829	21,567	18,225	15,001	14,589	12,659	9,721	7,030	6,810	6,341	5,997	3,854	3,311	2,903	2,749	1,893	1,524	1,389	1,391	523
Cashflow From Investing	-5.2%	-151,723	-144,241	4,895	-3,753	-2,950	-3,762	-11,419	-1,465	-533	30,149	844	-1,321	11,396	-25,929	33,919	67,241	-19,992	-501	-39,022	15,956	3,622
Cashflow From Financing	-389.0%	-10,115	3,500	14,934	5,631	7,289	224,125	619	3,044	4,076	3,843	3,479	3,550	4,521	2,312	126,445	787	897	192	1,241	-366	69,910

INSP Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 624,799	$ 407,856	$ 233,394
Cost of goods sold	96,576	66,115	33,279
Gross profit	528,223	341,741	200,115
Operating expenses:
Research and development	116,536	68,645	37,350
Selling, general and administrative	451,958	320,688	202,615
Total operating expenses	568,494	389,333	239,965
Operating loss	(40,271)	(47,592)	(39,850)
Other expense (income):
Interest and dividend income	(20,560)	(5,050)	(125)
Interest expense	0	1,677	2,128
Other expense, net	195	49	117
Total other (income) expense	(20,365)	(3,324)	2,120
Loss before income taxes	(19,906)	(44,268)	(41,970)
Income taxes	1,247	613	72
Net loss	(21,153)	(44,881)	(42,042)
Other comprehensive loss:
Foreign currency translation gain	140	89	0
Unrealized gain (loss) on investments	746	(120)	(84)
Total comprehensive loss	$ (20,267)	$ (44,912)	$ (42,126)
Net loss per share, basic (in dollars per share)	$ (0.72)	$ (1.60)	$ (1.54)
Net loss per share, diluted (in dollars per share)	$ (0.72)	$ (1.60)	$ (1.54)
Weighted average common shares used to compute net loss per share, basic (in shares)	29,302,154	28,071,748	27,262,979
Weighted average common shares used to compute net loss per share, diluted (in shares)	29,302,154	28,071,748	27,262,979

INSP Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 185,537	$ 441,592
Investments, short-term	274,838	9,821
Accounts receivable, net of allowance for credit losses of $1,648 and $36, respectively	89,884	61,228
Inventories, net	33,885	11,886
Prepaid expenses and other current assets	9,595	5,505
Total current assets	593,739	530,032
Investments, long-term	9,143	0
Property and equipment, net	39,984	17,249
Operating lease right-of-use assets	22,667	6,880
Other non-current assets	11,278	10,715
Total assets	676,811	564,876
Current liabilities:
Accounts payable	38,839	26,847
Accrued expenses	39,266	34,339
Total current liabilities	78,105	61,186
Operating lease liabilities, non-current portion	24,846	7,536
Other non-current liabilities	1,346	146
Total liabilities	104,297	68,868
Stockholders' equity
Preferred Stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding	0	0
Common Stock, $0.001 par value, 200,000,000 shares authorized; 29,560,464 and 29,008,368 shares issued and outstanding at December 31, 2023 and 2022, respectively	30	29
Additional paid-in capital	917,107	820,335
Accumulated other comprehensive income (loss)	800	(86)
Accumulated deficit	(345,423)	(324,270)
Total stockholders' equity	572,514	496,008
Total liabilities and stockholders' equity	$ 676,811	$ 564,876
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued expenses	Accrued expenses

About Inspire Medical Systems Inc

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

CEO	Mr. Timothy P. Herbert
WEBSITE	inspiresleep.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	755

Inspire Medical Systems Inc Frequently Asked Questions

What is the ticker symbol for Inspire Medical Systems Inc? What does INSP stand for in stocks?

INSP is the stock ticker symbol of Inspire Medical Systems Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inspire Medical Systems Inc (INSP)?

As of Wed Apr 17 2024, market cap of Inspire Medical Systems Inc is 7.2 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INSP stock?

You can check INSP's fair value in chart for subscribers.

What is the fair value of INSP stock?

You can check INSP's fair value in chart for subscribers. The fair value of Inspire Medical Systems Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inspire Medical Systems Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INSP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inspire Medical Systems Inc a good stock to buy?

The fair value guage provides a quick view whether INSP is over valued or under valued. Whether Inspire Medical Systems Inc is cheap or expensive depends on the assumptions which impact Inspire Medical Systems Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INSP.

What is Inspire Medical Systems Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, INSP's PE ratio (Price to Earnings) is -340.58 and Price to Sales (PS) ratio is 11.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INSP PE ratio will change depending on the future growth rate expectations of investors.